Search - tctmd.com

Displaying 161 - 180 of 292

Sort: Relevancy | Date

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for March 2025

Caitlin E. Cox

April 01, 2025

News Conference News ACC 2025

PCI Rebounds at 5 Years to Mostly Match CABG: Final FAME 3 Data

Caitlin E. Cox

March 31, 2025

News Conference News ACC 2025

Shelf-stable Product May Sub in for Frozen Plasma in Cardiac Surgery: FARES-II

L.A. McKeown

March 31, 2025

News Conference News ACC 2025

By 2 Years, Tricuspid TEER Reduces Hospitalizations for HF: TRILUMINATE

Michael O'Riordan

March 31, 2025

News Conference News EHRA 2025

Chronic HF Patients Needing CRT Fare Better With LBB Pacing: HeartSync-LBBP

Todd Neale

March 31, 2025

News Conference News ACC 2025

Evolut Low Risk Trial: TAVI Holds Up to Surgery at 5 Years

L.A. McKeown

March 30, 2025

News Conference News ACC 2025

More ALIGN-AR Data Bolster Potential for a Dedicated AR Device

Yael L. Maxwell

March 30, 2025

News Conference News ACC 2025

Dapagliflozin Works Well for High-Risk TAVI Patients With HF: DapaTAVI

Caitlin E. Cox

March 30, 2025

News Conference News ACC 2025

Strike Two: BHF PROTECT-TAVI Throws Cold Water on Embolic Protection

Michael O'Riordan

March 30, 2025

News Conference News ACC 2025

SOUL: Oral Semaglutide Bests Usual Care in High-Risk Type 2 Diabetes

Michael O'Riordan

March 29, 2025

Presentation ACC 2025

Advance-HTN: Lorundrostat Efficacy and Safety in Patients with Uncontrolled Hypertension

Presenter: Luke Laffin

March 29, 2025

Presentation ACC 2025

Oral Semaglutide Reduces Cardiovascular Events in People with Type 2 Diabetes with Atherosclerotic Cardiovascular and/or Chronic Kidney Disease: Primary Results From the SOUL Randomized Trial

Presenter: Darren K. McGuire

March 29, 2025

News Daily News ACC 2025

STRIDE: GLP-1 Boosts Walking Capacity in Diabetic PAD Patients

L.A. McKeown

March 29, 2025

Presentation ACC 2025

Four-Factor Prothrombin Complex Concentrate is Superior to Frozen Plasma in Bleeding Adult Cardiac Surgery Patients with Coagulopathy—Results from a Phase 3, Randomized, Active-Control Study

Presenter: Keyvan Karkouti

March 29, 2025

News Conference News ACC 2025

WARRIOR: No Clear Answers on How to Best Treat INOCA

Yael L. Maxwell

March 29, 2025

News Conference News ACC 2025

Low-Dose Apixaban Prevents Recurrent VTE in Cancer Beyond 6 Months: API-CAT

Caitlin E. Cox

March 29, 2025

News Opinion Conversations in Cardiology

Cath Lab Attire: ‘Dress Up and Shut Up’ or Time for a Change?

March 28, 2025

News Features

What’s in a Name: Is It Time to Choose Between TAVI and TAVR?

Yael L. Maxwell

March 27, 2025

News Daily News

Risk of Another Event Remains High for Years After TIA, Minor Stroke

Todd Neale

March 26, 2025

News Daily News

ISCHEMIA: No Clinical Event Reduction With Invasive Strategy in CTO Patients

Michael O'Riordan

March 26, 2025

Advertisement

TCTMD’s Top 10 Most Popular Stories for March 2025

PCI Rebounds at 5 Years to Mostly Match CABG: Final FAME 3 Data

Shelf-stable Product May Sub in for Frozen Plasma in Cardiac Surgery: FARES-II

By 2 Years, Tricuspid TEER Reduces Hospitalizations for HF: TRILUMINATE

Chronic HF Patients Needing CRT Fare Better With LBB Pacing: HeartSync-LBBP

Evolut Low Risk Trial: TAVI Holds Up to Surgery at 5 Years

More ALIGN-AR Data Bolster Potential for a Dedicated AR Device

Dapagliflozin Works Well for High-Risk TAVI Patients With HF: DapaTAVI

Strike Two: BHF PROTECT-TAVI Throws Cold Water on Embolic Protection

SOUL: Oral Semaglutide Bests Usual Care in High-Risk Type 2 Diabetes

Advance-HTN: Lorundrostat Efficacy and Safety in Patients with Uncontrolled Hypertension

Oral Semaglutide Reduces Cardiovascular Events in People with Type 2 Diabetes with Atherosclerotic Cardiovascular and/or Chronic Kidney Disease: Primary Results From the SOUL Randomized Trial

STRIDE: GLP-1 Boosts Walking Capacity in Diabetic PAD Patients

Four-Factor Prothrombin Complex Concentrate is Superior to Frozen Plasma in Bleeding Adult Cardiac Surgery Patients with Coagulopathy—Results from a Phase 3, Randomized, Active-Control Study

WARRIOR: No Clear Answers on How to Best Treat INOCA

Low-Dose Apixaban Prevents Recurrent VTE in Cancer Beyond 6 Months: API-CAT

Cath Lab Attire: ‘Dress Up and Shut Up’ or Time for a Change?

What’s in a Name: Is It Time to Choose Between TAVI and TAVR?

Risk of Another Event Remains High for Years After TIA, Minor Stroke

ISCHEMIA: No Clinical Event Reduction With Invasive Strategy in CTO Patients

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content